SCIENCE@home

Lenalidomide in patients with Relapsed or Refractory HTLV-1 Related Adult T cell Leukemia/Lymphoma (ATLL)

A. Phillips,Jalanni Giddings,Shing M. Lee,S. Horwitz

Published 2015 in Unknown venue

ABSTRACT

Adult T-cell Leukemia/Lymphoma (ATLL) is resistant to chemotherapy and the acute and lymphomatous subtypes of disease have a dismal prognosis. There is no standard therapy for relapsed or refractory disease in Western countries and new agents are being explored. Lenalidomide is an immunomodulatory agent with promising activity in hematologic malignancies, including non-Hodgkin's lymphoma and represents a novel therapeutic option. We investigated the safety and efficacy of lenalidomide (25 mg once daily) on Days 1 to 21 of every 28-day cycle in a phase two study of patients with relapsed or refractory ATLL. The study was closed early due to limited patient accrual. Of 4 patients enrolled, no response was observed in two patients evaluable for response. No grade 3 or 4 toxicity was noted. In this small single institution experience, lenalidomide showed no clinical activity and manageable toxicity in two evaluable patients with relapsed or refractory ATLL. This experience highlights the need for collaborative studies of this rare disease and enrolling patients on clinical trials promptly.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-13 of 13 references · Page 1 of 1

CITED BY

Showing 1-8 of 8 citing papers · Page 1 of 1